Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CASI Pharmaceuticals, Inc. - Ordinary Shares
(NQ:
CASI
)
0.7650
-0.0250 (-3.16%)
Streaming Delayed Price
Updated: 3:15 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CASI Pharmaceuticals, Inc. - Ordinary Shares
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
December 23, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
December 11, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
December 08, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Changes in Board Governance
November 19, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
November 14, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
November 10, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
November 04, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
November 03, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Appoints James Huang to Board of Directors
September 26, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
September 08, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
September 02, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
August 29, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
August 28, 2025
Via
ACCESS Newswire
Loop Industries (NASDAQ: LOOP) Ignites Paradigm Shift – Twist™ A Breakthrough in Circular Sustainability – More Stocks Inside
August 04, 2025
Via
AB Newswire
Topics
Economy
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
August 04, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
July 21, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Provides Business and Clinical Update
May 19, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
May 16, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
May 12, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
May 07, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
April 03, 2025
Via
ACCESS Newswire
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
March 31, 2025
Via
ACCESS Newswire
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
January 06, 2025
Via
ACCESSWIRE
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
November 15, 2024
Via
ACCESSWIRE
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
October 24, 2024
Via
ACCESSWIRE
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
December 10, 2021
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class...
From
BioInvent International
Via
AccessWire
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026
August 24, 2021
Via
FinancialNewsMedia
Topics
Death
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
